Antimicrobial resistance in gram-positive bacteria: The myth of the MIC

Pharmacotherapy

Volumn 19, Issue 8 SUPPL., 1999, Pages

  Rapp, Robert P ^a  

^a University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; DALFOPRISTIN PLUS QUINUPRISTIN; METICILLIN; OXACILLIN; PENICILLIN BINDING PROTEIN; PENICILLIN DERIVATIVE; VANCOMYCIN;

ANALYTICAL ERROR; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONFERENCE PAPER; GRAM POSITIVE BACTERIUM; LABORATORY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PENICILLIN RESISTANCE; STANDARD; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 0032765572     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.12.112S.31703     Document Type: Conference Paper

References (40)

1. Chin GJ, Marx J. Resistance to antibiotics. Science 1994;264:359.
2. Travis J. Reviving the antibiotic miracle? Science 1994;254:360-2.
3. Jacoby GA, Archer GL. New mechanisms of bacterial resistance to antimicrobial agents. N Engl J Med 1991;324:603-12.
4. Murray BE. New aspects of antimicrobial resistance and the resulting therapeutic dilemmas. J Infect Dis 1991;16:1185-94.
5. Gaynes R. The impact of antimicrobial use on the emergence of antimicrobial-resistant bacteria in hospitals. Infect Dis Clin North Am 1997;11:757-65.
6. Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance: report of the national nosocomial resistance surveillance group. Diagn Microbiol Infect Dis 1992;15: 37S-42.
7. Amsterdam D. The MIC: myth and reality. Antimicrobial Newsletter 1992;8:9-16.
8. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
9. Vogelman B, Gudmundsson S, Legget J, et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1998;158:831-47.
10. World Health Organization. Standardization of methods for conducting microbic sensitivity tests. Second report of the expert committee on antibiotics. Geneva: World Health Organization, 1961:1-24.
11. Amsterdam D. Susceptibility testing of antimicrobials in liquid media. In: Lorian V, ed. Antibiotics in clinical medicine, 2nd ed. Baltimore: Williams & Wilkins, 1991:53-105.
12. Baker CNS, Stocker SA, Rhoden DL, Thornsberry C. Evaluation of the MicroScan antimicrobial susceptibility system with the AugoScan-4 automated reader. J Clin Microbiol 1986;19:744-7.
13. National Committee for Clinical Laboratory Standards. MIC interpretative performance standards (μg/ml) for aerobic bacteria. Villanova, PA: NCCLS, 1999:68-93.
14. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests, 4th ed. Villanova, PA: NCCLS, 1990:M2-A4.
15. Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966;45:493-6.
16. Huang MP, Baker CN, Banerjee SN, Tenover FC. Accuracy of the E test for determining antimicrobial susceptibilities of staphylococci, enterococci, Campylobacter jejunii and gram-negative bacteria resistant to antimicrobial agents. J Clin Microbiol 1992;30:3243-8.
17. Woods GL, Washington JA. Antimicrobial agents and susceptibility testing. In: Tenover FC, ed. Manual of clinical microbiology, 6th ed. Washington, DC: ASM Press, 1995;1327-41.
18. Gehanno P, Nguyen L, Barry B, et al. Eradication by ceftriaxone of Streptococcus pneumoniae isolates with increased resistance to penicillin in cases of acute otitis media. Antimicrob Agents Chemother 1999;43:16-20.
19. Jacobs MR, Dagan R, Appelbaum PC, Burch DJ. Prevalence of antimicrobial resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media. Antimicrob Agents Chemother 1998;42:589-95.
20. Gold HS, Moellering RC. Antimicrobial-drug resistance. N Engl J Med 1996;335:1445-53.
21. Friedland IR, McCracken GH. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994;331:377-82.
22. Anonymous. National nosocomial infections surveillance system report, data summary from October 1986-April 1998. Washington, DC: Hospital Infections Program, Centers for Disease Control, 1998:1-25.
23. Applebaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992;15:77-83.
24. Gootz TD, Zaniewski R, Haskell S, et al. Activity of the new fluoroquinolone trovafloxacin (CP99, 219) against DNA gyrase and topoisomerase IV mutations of Streptococcus pneumoniae selected in vivo. Antimicrob Agents Chemother 1996;40:2691-7.
25. Panlilio AL, Culver DN, Gaynes RP, et al. Methicillin resistant S. aureus in US hospital 1975-1991. Infect Control Hosp Epidemiol 1992;13:582-8.
26. Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA, Schentag JJ. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis 1998;31:437-51.
27. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340:517-23.
28. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus working group. N Engl J Med 1999;340:493-501.
29. Waldvogel FA. New resistance in Staphylococcus aureus [editorial]. N Engl J Med 1999;340:556-7.
30. Kloos WE, Bannerman TL. Update on clinical significant of coagulase-negative staphylococci. Clin Microbiol Rev 1994;7:117-40.
31. Murray BE. The life and times of the enterococcus. Clin Microbiol Rev 1990;3:46-65.
32. French GL. Enterococci and vancomycin resistance. Clin Infect Dis 1998;27(suppl 1):S75-83.
33. Woo-Joo K, Weinstein RA, Hayden MK. The changing molecular epidemiology and establishment of endemicity of vancomycin resistance in enterococci at one hospital over a 6-year period. J Infect Dis 1999;179:163-71.
34. Goetz AM, Rihs JD, Wagener MM, Muder RR. Infection and colonization with vancomycin-resistant Enterococcus faecium in an acute care Veterans Affairs Medical Center: a 2-year survey. Am J Infect Control 1998;26:558-62.
35. Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: foes vancomycin resistance make a difference. Arch Intern Med 1998;158:522-7.
36. Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-13.
37. Bradley SA, Wilson ALT, Allen MC, Sher HA, Goldstone AH, Scott GM. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic use. J Antimicrob Chemother 1999;43:261-6.
38. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996;23:1020-5.
39. Hoskin GA, Peterson LR, Warren JR. Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. Clin Infect Dis 1995;20:296-301.
40. Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996;23:7657-72.